Milvexian (BMS-986177), an effective antithrombotic agent, is an orally-bioavailable, reversible and direct inhibitor of human and rabbit factor XIa (FXIa) with Ki of 0.11, and 0.38 nM, respectively.
Synonyms:
11,15-Metheno-15H-pyrazolo[4,3-b][1,7]diazacyclotetradecin-5(6H)-one, 10-[4-[5-chloro-2-(4-chloro-1H-1,2,3-triazol-1-yl)phenyl]-6-oxo-1(6H)-pyrimidinyl]-1-(difluoromethyl)-1,4,7,8,9,10-hexahydro-6-methyl-, (6R,10S)-;
BMS-986177
Properties:
density: 1.60±0.1 g/cm3(Predicted)
pka: 13.42±0.60(Predicted)
Factor Xa Related Products:
Apixaban; Rivaroxaban; Fondaparinux sodium; Betrixaban; Edoxaban tosylate